R2 lands distribution partner for Japan
Mammography CAD developer R2 Technology of Los Altos, CA, has signed a product distribution deal with Marubeni America that gives Marubeni rights to sell its ImageChecker product in Japan. The deal extends for three years and is subject to minimum
Mammography CAD developer R2 Technology of Los Altos, CA, has signed a product distribution deal with Marubeni America that gives Marubeni rights to sell its ImageChecker product in Japan. The deal extends for three years and is subject to minimum purchase requirements. R2 executives believe that Japan will establish a national mammography screening program within the next two years, creating demand for ImageChecker.
In related news, R2 closed a $6 million round of venture financing last month, with Marubeni America and its parent firm, Marubeni Corp., joining with R2s other financial backers in plowing more cash into the firm. R2 said it would use the money to finance its marketing efforts for ImageChecker in the U.S. and Japan.
© 1999 Miller Freeman, Inc.All rights reserved.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
